Product Pipeline - Pear Therapeutics

	Therapeutic Area/Indication	Development Stage
		Discovery Proof of Concept Pivotal Commercial
	Substance use disorder
	Opioid use disorder
	Chronic insomnia
Pear-009	Alcohol use disorder
Pear-004	Schizophrenia
Pear-011	Anxiety (GAD)
Pear-015	Depression (MDD)
Pear-017	Bipolar
Pear-005	Posttraumatic stress disorder

Pear-010	Acute and chronic pain
Pear-014	Migraine
Pear-006	Multiple sclerosis
Pear-013	Epilepsy

Pear-012	Irritable bowel syndrome
Pear-018	Specialty gastroenterology
Pear-016	Oncology
Pear-019	Cardiovascular

Abbreviations: GAD, generalized anxiety disorder; MDD, major depressive disorder.

*Dartmouth transaction is with a researcher employed by Dartmouth. Pear has
no direct contractual relationship with Dartmouth relating to this content.
^†Karolinska transaction is with individual researchers who are employed by the
Karolinska Institute. Pear has no direct contractual relationship with the
Karolinkska Institute relating to this content.
^‡Services agreement with Ironwood to evaluate a PDT in gastrointestinal diseases.

PLATFORM
ENHANCEMENTS

DIGITAL BIOMARKERS

Voice

Keystroke

Adherence
Sensors

Physiologic
Monitoring